Skip to content
10-Q

Quarterly Report

Kyverna Therapeutics, Inc. KYTX

0001193125-26-219397

← back to feed
Filed
May 12, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 1, 2026 60.8M sh
Shares Diluted Q1 2026 · Mar 31, 2026 60.43M sh
Shares Diluted Q1 2026 · Mar 31, 2025 43.22M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$41.6M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$44.92M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $32.19M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $124.09M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $56.87M
Stockholders Equity Q1 2026 · Mar 31, 2026 $195.58M
Stockholders Equity Q1 2026 · Dec 31, 2025 $232.28M
Stockholders Equity Q1 2026 · Mar 31, 2025 $224.01M
Stockholders Equity Q1 2026 · Dec 31, 2024 $266.59M
Current Liabilities Q1 2026 · Mar 31, 2026 $29.67M
Current Liabilities Q1 2026 · Dec 31, 2025 $36.49M
Total Liabilities Q1 2026 · Mar 31, 2026 $61.44M
Total Liabilities Q1 2026 · Dec 31, 2025 $61.55M
Current Assets Q1 2026 · Mar 31, 2026 $241.73M
Current Assets Q1 2026 · Dec 31, 2025 $282.95M
Total Assets Q1 2026 · Mar 31, 2026 $257.02M
Total Assets Q1 2026 · Dec 31, 2025 $293.83M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.66
Eps Diluted Q1 2026 · Mar 31, 2025 −$1.03
Eps Basic Q1 2026 · Mar 31, 2026 −$0.66
Eps Basic Q1 2026 · Mar 31, 2025 −$1.03
Sga Expense Q1 2026 · Mar 31, 2026 $11.29M
Sga Expense Q1 2026 · Mar 31, 2025 $9.98M
Rd Expense Q1 2026 · Mar 31, 2026 $30.07M
Rd Expense Q1 2026 · Mar 31, 2025 $37.43M
Net Income Q1 2026 · Mar 31, 2026 −$39.73M
Net Income Q1 2026 · Mar 31, 2025 −$44.64M
Operating Income Q1 2026 · Mar 31, 2026 −$41.37M
Operating Income Q1 2026 · Mar 31, 2025 −$47.41M